An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase I
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Brodalumab (Primary) ; Midazolam
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Amgen
- 29 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Dec 2014, according to the ClinicalTrials.gov record.
- 31 Jul 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2014 to 1 Oct 2014.